CRISPR-Based Therapy for Hereditary Angioedema.
Cohn DM, Gurugama P, Magerl M, Katelaris CH, Launay D, Bouillet L, Petersen RS, Lindsay K, Aygören-Pürsün E, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Abdelhady AM, Lebwohl D, Longhurst HJ
- DOI
- 10.1056/NEJMoa2405734
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-22
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/2a37fd9d-c89a-45a6-a508-579c4be88f5b is authoritative.
How this rating was calculated
- ClaimsOverstated claim ×2−1★
- ReportingData & code availability partially met−0.25★
- No reported statistical tests were found to recompute.
- No data or code availability links were detected to verify.
- 01Conclusion reaches beyond the evidence
A single dose of NTLA-2002 may provide lifelong control of angioedema attacks.
“A single dose of NTLA-2002 may provide lifelong control of angioedema attacks.”
IntroductionFind in source - 02Conclusion reaches beyond the evidence
NTLA-2002 has the potential to be a functional cure for hereditary angioedema.
These results show the potential of a single dose of the new CRISPR-Cas9–based in vivo gene-editing therapy NTLA-2002 to be a functional cure for patients with hereditary angioedema
Discussionreviewer’s wording
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted phase 2 randomized controlled trial of an in vivo CRISPR therapy for hereditary angioedema, with strong scientific premise, adequate design, and transparent reporting. The main weaknesses are the lack of a formal power analysis, incomplete description of randomization and statistical software, and a vague data sharing statement. The claim of 'functional cure' is somewhat overstated given the small sample and short follow-up.
Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification component checked 0 tests (none were machine-verifiable), so statistical correctness is not confirmed beyond the reported model. The claim audit flagged two overstatements.
Numerical inconsistencies
None foundValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
Checked — nothing surfaced.
Overstated conclusions
1 finding · worst mediumConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Conclusions overstated beyond the evidenceAssessed
4 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).
- overstatedReviewers 1, 2A single dose of NTLA-2002 may provide lifelong control of angioedema attacks.The claim of 'lifelong control' is speculative; the data show durable effects up to ~19 months in phase 1, but this does not establish lifelong control.Evidence: Phase 1 follow-up shows median follow-up of 20.1 months with sustained responses, but this is not lifelong.
“A single dose of NTLA-2002 may provide lifelong control of angioedema attacks.”
IntroductionFind in source - overstatedReviewers 1, 2NTLA-2002 has the potential to be a functional cure for hereditary angioedema.The term 'functional cure' is strong given the small sample size and short follow-up; the data are promising but not sufficient to claim a cure.Evidence: The trial shows reduced attacks and sustained kallikrein reduction, but long-term durability and safety are not fully established.
These results show the potential of a single dose of the new CRISPR-Cas9–based in vivo gene-editing therapy NTLA-2002 to be a functional cure for patients with hereditary angioedema
Discussionreviewer’s wording - supportedReviewers 1, 2NTLA-2002 reduced angioedema attacks compared with placebo.The primary end point analysis shows a substantial reduction in monthly attack rate with both doses compared with placebo, with confidence intervals that do not include zero for the percent difference.Evidence: Estimated mean monthly attack rate 0.70 (25 mg) and 0.65 (50 mg) vs 2.82 (placebo); percent difference -75% and -77% with 95% CIs.
the estimated mean monthly attack rate was 0.70 (95% confidence interval [CI], 0.25 to 1.98) with 25 mg of NTLA-2002, 0.65 (95% CI, 0.24 to 1.76) with 50 mg, and 2.82 (95% CI, 0.80 to 9.89) with placebo; the difference in the estimated mean attack rate with NTLA-2002 as compared with placebo was −75% with 25 mg and −77% with 50 mg.
Abstractreviewer’s wording - supportedReviewers 1, 2NTLA-2002 led to robust and sustained reduction in total plasma kallikrein levels.The pharmacodynamic data show dose-dependent reductions in kallikrein levels at week 16, and phase 1 follow-up data indicate durability.Evidence: Mean percent change from baseline to week 16 was -55% with 25 mg and -86% with 50 mg; phase 1 follow-up shows sustained reductions.
“The mean percent change in total plasma kallikrein protein levels from baseline to week 16 was −55% with 25 mg and −86% with 50 mg; levels remained unchanged with placebo.”
AbstractFind in source
Efficacy claim is anchored to an adequate endpoint and a meaningful effect.
- ADEQUATESurrogate endpointThe primary endpoint is the monthly attack rate, a direct clinical outcome (number of angioedema attacks per month), not a surrogate. The reduction in plasma kallikrein is a secondary pharmacodynamic endpoint supporting the mechanism, but the efficacy claim is based on the clinical attack rate.
“The primary end point was the number of angioedema attacks per month (the monthly attack rate) from week 1 through week 16.”
- ADEQUATEEffect sizeThe treatment reduced monthly attack rate by 75-77% compared to placebo, with 40-73% of patients attack-free. The effect is large and clinically meaningful, and the AE-QoL improvement exceeded the minimal clinically important difference of 6 points.
“the difference in the estimated mean attack rate with NTLA-2002 as compared with placebo was −75% with 25 mg and −77% with 50 mg.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction describes the pathophysiology of hereditary angioedema, the role of plasma kallikrein, and prior evidence that kallikrein inhibition reduces attacks. It also cites the phase 1 results of this same trial, providing a direct rationale for the phase 2 doses. Limitations of prior treatments (lifelong administration) are noted, and the premise is logically linked to the study objectives.
“Plasma kallikrein is clinically validated as a therapeutic target, with kallikrein inhibitors approved for long-term prophylaxis.”
“Previously reported results from the phase 1 dose-escalation portion of this phase 1–2 trial showed no dose-limiting toxic effects from a single infusion of NTLA-2002 at a dose of 25 mg, 50 mg, or 75 mg.”
“Plasma kallikrein is clinically validated as a therapeutic target, with kallikrein inhibitors approved for long-term prophylaxis.”
The trial is described as double-blind, randomized, and placebo-controlled with a 2:2:1 allocation ratio. Randomization method is not detailed (e.g., no mention of a random number generator or stratification), but the unit is the patient. Blinding is stated as double-blind. The sample size was not determined by a formal power analysis, which is a limitation but explicitly acknowledged. Inclusion/exclusion criteria are described, and the analysis populations (full analysis and safety) are defined. The comparator is placebo, and no independent replication is expected for a single pivotal trial.
“Patients were randomly assigned in a 2:2:1 ratio to receive NTLA-2002 administered intravenously in a single dose of 25 mg or 50 mg or a placebo saline solution.”
“Patients were randomly assigned in a 2:2:1 ratio to receive NTLA-2002 administered intravenously in a single dose of 25 mg or 50 mg or a placebo saline solution.”
The paper reports sex, age, race/ethnicity, weight, and disease type in Table 1. Both sexes are enrolled, so sex_justified is not applicable. Age and weight are reported as medians with ranges. Demographics are adequately reported. Species/strain and housing conditions are not applicable for a human trial.
“Median age (range) — yr 48.5 (34–61) 44.0 (18–61) 47.0 (31–76)”
“Male sex — no. (%) 7 (70) 5 (45) 2 (33)”
The paper states that the trial was approved by the institutional review board or ethics committee at each participating site, and that all patients provided written informed consent. It also states compliance with the Declaration of Helsinki and ICH-GCP guidelines. This satisfies all applicable criteria for a human interventional trial.
“The trial was approved by the institutional review board or ethics committee at each participating trial site.”
“The trial was approved by the institutional review board or ethics committee at each participating trial site.”
NTLA-2002 is described as a CRISPR-Cas9-based therapy targeting KLKB1, with dose and administration route specified. The manufacturer (Intellia Therapeutics) is identified as the sponsor. No other biological or chemical reagents are used. Statistical software is not named, but this is not a key resource for a clinical trial. The trial is scored because the investigational product is a resource.
“NTLA-2002 administered intravenously in a single dose of 25 mg or 50 mg or a placebo saline solution.”
“Patients were randomly assigned in a 2:2:1 ratio to receive NTLA-2002 administered intravenously in a single dose of 25 mg or 50 mg or a placebo saline solution.”
The primary analysis used a negative binomial regression model, which is appropriate for count data. The paper reports effect estimates with 95% confidence intervals, and explicitly states that no formal statistical testing was planned. Exact p-values are not reported, but this is consistent with the estimation-based approach. Assumptions are not explicitly verified, but the model choice is standard. Statistical software is not identified. Data presentation includes per-group n and confidence intervals.
“We analyzed the primary end point using a negative binomial regression model, adjusting for the baseline monthly attack rate.”
“the estimated mean monthly attack rate (adjusted for the baseline value) was 0.70 (95% confidence interval [CI], 0.25 to 1.98) in the 25-mg group”
“No formal statistical testing was planned.”
“We analyzed the primary end point using a negative binomial regression model, adjusting for the baseline monthly attack rate.”
“The mean difference in the monthly attack rate with NTLA-2002 as compared with placebo was −75% (95% CI, −95 to 27) with 25 mg and −77% (95% CI, −95 to 15) with 50 mg”
“No formal statistical testing was planned.”
The paper states 'A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.' This indicates a statement exists but its content is not provided in the text. For a clinical trial, managed access is acceptable, but the specific mechanism is not described here. No code sharing is mentioned, and no data repository or accession numbers are provided.
“A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.”
“A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.”
The trial is registered (ClinicalTrials.gov NCT05120830 and EudraCT number). Methods are described in sufficient detail for replication. Limitations are explicitly discussed, including small sample size, nonstratified randomization, and short follow-up. Conclusions are appropriately cautious, noting the need for a phase 3 trial. Funding and COI are disclosed. A reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows standard reporting.
“Potential limitations of this trial include the small sample size, nonstratified randomization, the short duration of follow-up, and a primary observation period of only 16 weeks.”
“Potential limitations of this trial include the small sample size, nonstratified randomization, the short duration of follow-up, and a primary observation period of only 16 weeks.”
Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
None found · partly checkedReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.
Checked 24 references by DOI: 1 verified — 23 no DOI (shown, not verified).
- NO DOIThe international WAO/EAACI guideline for the management of hereditary angioedema — the 2021 revision and updateNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIUS HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIColonic intussusception secondary to hereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIOptimal management of hereditary angioedema: shared decision-makingNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDefinition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensusNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITakhzyro (lanadelumab-flyo) prescribing informationNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEffect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIOral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIOrladeyo (berotralstat) prescribing informationNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAntisense inhibition of prekallikrein to control hereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIInhibition of prekallikrein for hereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEfficacy and safety of donidalorsen for hereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPrevention of hereditary angioedema attacks with a subcutaneous C1 inhibitorNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINanofiltered C1 inhibitor concentrate for treatment of hereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedemaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe contact system in liver injuryNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICRISPR/Cas9-mediated KLKB1 gene editing and serum kallikrein reduction by NTLA-2002 remains durable in humanized mice following liver regeneration after partial hepatectomyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDiploid hepatocytes drive physiological liver renewal in adult humansNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICommon terminology criteria for adverse events (CTCAE), version 5.0No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe Angioedema Quality of Life Questionnaire (AE-QoL) — assessment of sensitivity to change and minimal clinically important differenceNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDiagnosis and screening of patients with hereditary angioedema in primary careNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
Copyediting
1 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 1 minor suggestion below.
1 copyedit issue flagged: mostly typo.
- MINORtypoAbstract, Results“4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free”→ Consider rephrasing for clarity: '4 of 10 patients (40%) in the 25-mg group and 8 of 11 (73%) in the 50-mg group were attack-free'Minor clarity issue.
The published work is robust overall, but an informed reader should weigh the small sample size, lack of formal power analysis, and the overstatement of 'functional cure' and 'lifelong control' claims. A correction or erratum is not strictly required, but the authors should consider tempering these claims in any future communications or provide additional evidence. The data sharing statement should be clarified.
- 1.HIGHrigorIn the Discussion, temper the claim that NTLA-2002 may provide 'lifelong control' of angioedema attacks, as the data only show durable effects up to ~19 months in phase 1.The claim of lifelong control is speculative and not supported by the current follow-up duration.
- 2.HIGHrigorIn the Discussion, temper the claim that NTLA-2002 has the 'potential to be a functional cure' for hereditary angioedema, given the small sample size and short follow-up.The term 'functional cure' is strong and may overstate the evidence; a more cautious phrasing is warranted.
- 3.HIGHreportingIn the Methods (Randomization and Treatment), describe the randomization method (e.g., computer-generated random sequence, block size, stratification) to improve reproducibility.The current description only states the allocation ratio, which is insufficient for replication.
- 4.HIGHstatisticsIn the Methods (Statistical Analysis), identify the statistical software and version used for the analysis.Software identification is a standard reporting requirement and aids reproducibility.
- 5.HIGHdata codeIn the Data Availability section, provide the specific data sharing statement content, including the mechanism for requesting data (e.g., via a data access committee or platform) and any conditions.The current statement is vague and does not specify how readers can access the data.
- 6.MEDIUMreportingIn the Methods (Trial Design and Oversight), explicitly mention adherence to CONSORT reporting guidelines, or provide a completed CONSORT checklist as supplementary material.Explicit adherence to reporting guidelines enhances transparency and completeness.
- 7.MEDIUMstatisticsIn the Methods (Statistical Analysis), add a statement on whether assumptions of the negative binomial model were verified (e.g., overdispersion, goodness-of-fit).Verification of model assumptions strengthens the statistical analysis.
- 8.MEDIUMreportingIn the Methods (Randomization and Treatment), specify the method of blinding (e.g., identical placebo, sealed envelopes) to fully describe blinding procedures.Detailed blinding procedures are important for assessing risk of bias.
- 9.MEDIUMreportingIn the Discussion, expand on the limitations of the nonstratified randomization and its potential impact on baseline imbalances.Acknowledging this limitation helps readers interpret the results appropriately.
- 10.LOWcopyeditIn the Abstract, Results, rephrase '4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free' to '4 of 10 patients (40%) in the 25-mg group and 8 of 11 (73%) in the 50-mg group were attack-free' for clarity.The original phrasing is grammatically awkward and less clear.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.